Search
Crizotinib
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule...
Ceritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalThis occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. … Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA...
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.
Refractory Inflammatory Myofibroblastic Tumors
go.drugbank.com/conditions/DBCOND0150134Drugs: CrizotinibEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigationalwhen compared to [crizotinib]. … [A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib].
Unresectable Inflammatory Myofibroblastic Tumors
go.drugbank.com/conditions/DBCOND0150133Drugs: CrizotinibRecurrent Inflammatory Myofibroblastic Tumors
go.drugbank.com/conditions/DBCOND0150135Drugs: Crizotinib